Clinical Pharmacology

Doctor-supervised pharmacological interventions: off-label rapamycin, GLP-1s, HRT/TRT, senolytics, low-dose tadalafil, and the metformin/TAME frame. Each entry names regulatory status, published-trial reference dose at the order-of-magnitude level, and explicit non-candidate populations.

Start with Adult Immunization as Healthspan Preservation: the section’s least glamorous but most evidence-grounded clinical-prevention entry. Then read Rapamycin Off-Label Longevity Dosing: the section’s cleanest test of how to separate animal geroscience, early human surrogate trials, off-label prescribing, monitoring, and public enthusiasm. GLP-1 Receptor Agonists for Longevity-Adjacent Outcomes gives the opposite evidence shape: strong human disease-outcome trials in selected metabolic-risk populations, but no healthy-adult lifespan claim. Metformin and the TAME Frame sits between those examples by separating diabetes prevention, observational geroscience signals, and the still-unlaunched TAME outcomes design. Senolytics (Dasatinib + Quercetin, Fisetin) adds the cell-clearance version of the same problem: strong animal biology, early human marker and feasibility trials, and no broad healthy-adult lifespan proof. Calcium Alpha-Ketoglutarate (Ca-AKG / Rejuvant) gives the supplement version of the same discipline: a real mouse frailty-and-survival signal, an uncontrolled human methylation-clock case series, and placebo-controlled human trials still waiting to report efficacy. Hormone Replacement Therapy (Female: HRT/BHRT) adds the menopause-care version of the same discipline: candidate-specific evidence, formulation differences, timing, and the boundary between approved symptom treatment and broad longevity claims. Testosterone Replacement Therapy (TRT) applies that same candidate-specific frame to male hypogonadism, fertility, TRAVERSE-era cardiovascular evidence, prostate monitoring, and the line between replacement and performance-clinic escalation. Low-Dose Tadalafil (Off-Label Longevity Use) compares a cheaper off-label vascular-health claim against this section’s evidence-tier, candidate-group, regulatory-status, and non-claim boundaries: decades-old on-label evidence for erectile dysfunction, benign prostatic hyperplasia, and pulmonary arterial hypertension, an observational prescription-cohort dementia-incidence signal in men with erectile dysfunction, and the absence of randomized lifespan or healthspan trials in healthy adults.

Read straight through, or land on a specific entry and follow its outgoing links into the rest of the book.